Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.95 |
| ▸ | MEN1 | O00255 | 2/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.95 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.95 |
| ▸ | MAPT | P10636 | 2/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.91 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.91 |
| ▸ | SQLE | Q14534 | 7/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ICMT | O60725 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Geraniol SCHEMBL20533893 | 1.00 | KMT2A (0.95) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| Geraniol SCHEMBL9051249 | 0.97 | KMT2A (1.00) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| Nerol SCHEMBL3319949 | 0.97 | KMT2A (1.00) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| Geraniol SCHEMBL11280775 | 0.97 | KMT2A (1.00) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| Geraniol SCHEMBL19824 | 0.97 | KMT2A (1.00) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| Geraniol SCHEMBL2874022 | 0.97 | KMT2A (1.00) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| Geraniol SCHEMBL8676054 | 0.97 | KMT2A (1.00) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| Geraniol SCHEMBL118988 | 0.97 | KMT2A (1.00) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| Geraniol SCHEMBL21173796 | 0.97 | KMT2A (1.00) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| Geraniol SCHEMBL30529087 | 0.97 | KMT2A (1.00) | KMT2AMEN1CYP3A4ALOX15MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562009-B2 | Method for producing ruthenium/iron/carbon carrier catalysts | BASF SE (DE) | 2020-02-18 | — | — | US | disclosed |
| US-20180297013-A1 | METHOD FOR PRODUCING RUTHENIUM/IRON/CARBON CARRIER CATALYSTS | BASF SE (DE) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180297013-A1 | METHOD FOR PRODUCING RUTHENIUM/IRON/CARBON CARRIER CATALYSTS | FTH1, ADH5, FECH | KMT2A 4577/4885MEN1 1510/4885CYP3A4 542/4885 |
| US-10562009-B2 | Method for producing ruthenium/iron/carbon carrier catalysts | FTH1, ADH5, FECH | KMT2A 4577/4885MEN1 1510/4885CYP3A4 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.